Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Although immune mechanisms can suppress tumour growth, tumours establish potent, overlapping mechanisms that mediate immune evasion. Emerging evidence suggests a link between angiogenesis and the tolerance of tumours to immune mechanisms. Hypoxia, a condition that is known to drive angiogenesis in tumours, results in the release of damage-associated pattern molecules, which can trigger the rejection of tumours by the immune system. Thus, the counter-activation of tolerance mechanisms at the site of tumour hypoxia would be a crucial condition for maintaining the immunological escape of tumours. However, a direct link between tumour hypoxia and tolerance through the recruitment of regulatory cells has not been established. We proposed that tumour hypoxia induces the expression of chemotactic factors that promote tolerance. Here we show that tumour hypoxia promotes the recruitment of regulatory T (T(reg)) cells through induction of expression of the chemokine CC-chemokine ligand 28 (CCL28), which, in turn, promotes tumour tolerance and angiogenesis. Thus, peripheral immune tolerance and angiogenesis programs are closely connected and cooperate to sustain tumour growth.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hypoxia, through HIF-1α, drives the conversion of MDSCs into antigen-nonspecific suppressors of T cell function and promotes the differentiation of MDSCs into immune-suppressive TAMs, further potentiating the immune-suppressive network [80].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [80]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [181]
In the citing paper
“tumours secrete soluble factors, such as C-C-motif chemokine ligand 2 (CCL2), CCL28, C-X-C-motif chemokine ligand 8 (CXCL8), CXCL12, ANG2, VEGF, PlGF, and adenosine, all of which promote the recruitment of immunosuppressive cells7,17–20 (FIG. 2)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [17]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationSummaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Self-citationImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Cited by
Items 101–200 of 1,002
Monocytes in the Tumor Microenvironment
Ugel, S., Canè, S., De Sanctis, F., & Bronte, V. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-013058 · Cited by 314
Wang, B., Zhao, Q., Zhang, Y., Liu, Z., Zheng, Z., Liu, S., Meng, L., Xin, Y., & Jiang, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01820-7 · Cited by 315
“By binding to its receptor, CCR10, CCL28 can effectively recruit CCR10+ Treg cells to the tumor site, thus suppressing the functions of effector T-cells and promoting the tumor growth [44, 46].”
BackgroundImmunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Das, S., Singh, S., Dowding, J. M., Oommen, S., Kumar, A., Sayle, T. X. T., Saraf, S., Patra, C. R., Vlahakis, N. E., Sayle, D. C., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.07.019 · Cited by 309
“Angiogenesis can be induced either by inducing low levels of intracellular ROS [26] or by controlling the intracellular oxygen concentration to the cells [27].”
BackgroundMigrating into the tumor: a roadmap for T cells
van der Woude, L. L., Gorris, M. A. J., Halilovic, A., Figdor, C. G., & de Vries, I. J. M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.09.006 · Cited by 307
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
Sobhani, N., Tardiel-Cyril, D. R., Davtyan, A., Generali, D., Roudi, R., & Li, Y. (2021) · Cancers · doi:10.3390/cancers13061440 · Cited by 303
“This could indicate that Treg cells become activated in TME where they exert their immune suppressive functions [83].”
BackgroundBacteria‐Based Cancer Immunotherapy
Huang, X., Pan, J., Xu, F., Shao, B., Wang, Y., Guo, X., & Zhou, S. (2021) · Advanced Science · doi:10.1002/advs.202003572 · Cited by 304
Koyama, S., & Nishikawa, H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002591 · Cited by 305
Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer
Ali, H. R., Jackson, H. W., Zanotelli, V. R. T., Danenberg, E., Fischer, J. R., Bardwell, H., Provenzano, E., CRUK IMAXT Grand Challenge Team, Ali, H. R., Al Sa’d, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0026-6 · Cited by 306
“Collectively, our findings reveal that breast cancer genomic subtypes have diverse cellular compositions, including marked differences in stromal phenotypes and in patterns of cellular interaction. t-SNE 1 tS N E 2 44 53 43 11 31 35 17 2 2124 6 38 48 34 n = 141 Luminal A 14 27 3133 28 13 n = 100 Luminal B 16 32 46 33…”
BackgroundInfluentialBansal, S. S., Ismahil, M. A., Goel, M., Zhou, G., Rokosh, G., Hamid, T., & Prabhu, S. D. (2019) · Circulation · doi:10.1161/circulationaha.118.036065 · Cited by 300
The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis
Nishida, A., & Andoh, A. (2025) · Cells · doi:10.3390/cells14070488 · Cited by 270
“Moreover, hypoxia-induced upregulation of CCL28 in tumor cells enhances Treg recruitment, reinforcing the immunosuppressive tumor microenvironment [65].”
Exercise-dependent regulation of the tumour microenvironment
Koelwyn, G. J., Quail, D. F., Zhang, X., White, R. M., & Jones, L. W. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.78 · Cited by 296
Regulatory T cells in the treatment of disease
Sharabi, A., Tsokos, M. G., Ding, Y., Malek, T. R., Klatzmann, D., & Tsokos, G. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.148 · Cited by 297
Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
Sasidharan Nair, V., & Elkord, E. (2018) · Immunology & Cell Biology · doi:10.1111/imcb.1003 · Cited by 298
“through the ligation with CCR10, a cognate receptor expressed on Tregs.(39) In TME, the abundance of IL-10,(40) TGF-b,(41) and adenosine(42) produced by tumor cells and tumor-resident DCs promotes expansion of Tregs and generation of peripheral Tregs (pTregs).”
MethodCombining microenvironment normalization strategies to improve cancer immunotherapy
Mpekris, F., Voutouri, C., Baish, J. W., Duda, D. G., Munn, L. L., Stylianopoulos, T., & Jain, R. K. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919764117 · Cited by 286
White, G. E., Iqbal, A. J., & Greaves, D. R. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005074 · Cited by 289
“A very recent study suggests that CCL28-mediated Treg recruitment plays a role in tumor development (Facciabene et al., 2011).”
BackgroundDuraiswamy, J., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1550 · Cited by 278
“The role of Tregs in mediating immune suppression and tumor growth has been previously established in ovarian cancer (24, 31).”
BackgroundResultSelf-citationPlasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3498 · Cited by 269
Controlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3366 · Cited by 264
Revisiting the HIF switch in the tumor and its immune microenvironment.
Cowman, S. J., & Koh, M. Y. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2021.10.004 · Cited by 256
T Regulatory Cells and Priming the Suppressive Tumor Microenvironment
Paluskievicz, C. M., Cao, X., Abdi, R., Zheng, P., Liu, Y., & Bromberg, J. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02453 · Cited by 251
Tsilimigras, D. I., Sahara, K., Wu, L., Moris, D., Bagante, F., Guglielmi, A., Aldrighetti, L., Weiss, M., Bauer, T. W., Alexandrescu, S., et al. (2020) · JAMA Surgery · doi:10.1001/jamasurg.2020.1973 · Cited by 242
Natural and Induced T Regulatory Cells in Cancer
Adeegbe, D. O., & Nishikawa, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00190 · Cited by 248
“Other chemokine receptors implicated in Treg trafficking to tumor sites include CXCR4, which drives Treg cells toward tumor site via interactions with CXCL12 that is produced within the tumor microenvironment, as well as CCR8 and CCR10 (86–88).”
BackgroundNatural killer group 2D receptor and its ligands in cancer immune escape
Duan, S., Guo, W., Xu, Z., He, Y., Liang, C., Mo, Y., Wang, Y., Xiong, F., Guo, C., Li, Y., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0956-8 · Cited by 244
“For example, in ovarian cancer, tumor cells secrete CCL28 to recruit Tregs [34]; hypoxia-inducible factor-1 (HIF-1) induced by hypoxia directly downregulates Foxp3 expression by combining with the Foxp3 promoter region, inducing Treg formation [35], and regulates the function and differentiation of MDSCs [36].”
BackgroundInfluentialAutophagy regulation and its role in cancer
Lorin, S., Hamaï, A., Mehrpour, M., & Codogno, P. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.06.007 · Cited by 245
Ott, P. A., Hodi, F. S., & Buchbinder, E. I. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00202 · Cited by 242
“In a mouse ovarian cancer model, tumor hypoxia resulted in the recruitment of Tregs through upregulation of the chemokine ligand 28 (CCL28), leading to increased tumor growth (29, 30).”
BackgroundWang, H., Han, X., Dong, Z., Xu, J., Wang, J., & Liu, Z. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201902440 · Cited by 244
Tumor microenvironment components: Allies of cancer progression
Ribeiro Franco, P. I., Rodrigues, A. P., de Menezes, L. B., & Pacheco Miguel, M. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152729 · Cited by 237
Chiu, D. K., Xu, I. M., Lai, R. K., Tse, A. P., Wei, L. L., Koh, H., Li, L. L., Lee, D., Lo, R. C., Wong, C., et al. (2016) · Hepatology · doi:10.1002/hep.28655 · Cited by 241
“Of note, CCL28 has been previously reported as central regulator of Treg cell recruitment (17), whereas the roles of CCL26 remain to be elucidated.”
Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment
Casazza, A., Di Conza, G., Wenes, M., Finisguerra, V, Deschoemaeker, S., & Mazzone, M. (2014) · Oncogene · doi:10.1038/onc.2013.121 · Cited by 243
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment
Liu, G., Rui, W., Zhao, X., & Lin, X. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00655-2 · Cited by 237
Hypoxia: Signaling the Metastatic Cascade
Rankin, E. B., Nam, J.-M., & Giaccia, A. J. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.05.006 · Cited by 239
“Recent studies indicate that HIF signaling can also be activated within tumor stromal cells through a variety of mechanisms including hypoxia and secreted factors produced by tumor cells [40, 75].”
BackgroundDo, H. T. T., Lee, C. H., & Cho, J. (2020) · Cancers · doi:10.3390/cancers12020287 · Cited by 234
“The recruitment of Treg cells to TME is mediated by chemotaxis of CCL20/CCR6 [34], CCL22/CCR4 [35], CCL28/CCR10 [36], and CXCL12/CXCR4 [37,38].”
BackgroundMcNamee, E. N., Korns Johnson, D., Homann, D., & Clambey, E. T. (2013) · Immunologic Research · doi:10.1007/s12026-012-8349-8 · Cited by 234
“Recent work analyzing the link between cancer, hypoxia, and tumor-protective effects demonstrated that tumor-associated hypoxia induces the expression of chemokine CCL28, which selectively induces the recruitment of regulatory T cells (Tregs) leading to induction of tumor tolerance and neoangiogenesis [83].”
BackgroundTargeting tumor microenvironment in ovarian cancer: Premise and promise
Jiang, Y., Wang, C., & Zhou, S. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188361 · Cited by 232
Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy
Wang, H., Franco, F., & Ho, P.-C. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.06.005 · Cited by 234
Meng, X., Zhang, J., Sun, Z., Zhou, L., Deng, G., Li, S., Li, W., Gong, P., & Cai, L. (2018) · Theranostics · doi:10.7150/thno.26607 · Cited by 230
“Hypoxia has been widely reported to cause chemo- or radiation-resistance, which significantly undermine the efficacy of cancer therapies [4-6, 32-33].”
BackgroundHypoxia and acidosis: immune suppressors and therapeutic targets
Damgaci, S., Ibrahim‐Hashim, A., Enriquez‐Navas, P. M., Pilon‐Thomas, S., Guvenis, A., & Gillies, R. J. (2018) · Immunology · doi:10.1111/imm.12917 · Cited by 231
Targeting regulatory T cells in tumors
Liu, C., Workman, C. J., & Vignali, D. A. A. (2016) · The FEBS Journal · doi:10.1111/febs.13656 · Cited by 228
Microfluidic modelling of the tumor microenvironment for anti-cancer drug development
Shang, M., Soon, R. H., Lim, C. T., Khoo, B. L., & Han, J. (2019) · Lab on a Chip · doi:10.1039/c8lc00970h · Cited by 227
Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma
Wang, X., Lang, M., Zhao, T., Feng, X., Zheng, C., Huang, C., Hao, J., Dong, J., Luo, L., Li, X., et al. (2017) · Oncogene · doi:10.1038/onc.2016.458 · Cited by 227
Deng, J., Li, J., Sarde, A., Lines, J. L., Lee, Y.-C., Qian, D. C., Pechenick, D. A., Manivanh, R., Le Mercier, I., Lowrey, C. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0507 · Cited by 224
“14, 15) and MDSCs by upregulating the chemokine CCL28 (16) and numerous CXC family members (15), respectively.”
BackgroundBlocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer
Su, S., Liao, J., Liu, J., Huang, D., He, C., Chen, F., Yang, L., Wu, W., Chen, J., Lin, L., et al. (2017) · Cell Research · doi:10.1038/cr.2017.34 · Cited by 225
Regulatory T‐cell homeostasis: steady‐state maintenance and modulation during inflammation
Smigiel, K. S., Srivastava, S., Stolley, J. M., & Campbell, D. J. (2014) · Immunological Reviews · doi:10.1111/imr.12170 · Cited by 222
“(121) demonstrated that hypoxia induced CCL28 expression by tumor cells promoted the recruitment of CCR10 Treg cells into the hypoxic tumor microenvironment, and that the newly recruited Treg cells produced VEGFA and promoted tumor angiogenesis.”
BackgroundChiang, C. L.-L., Kandalaft, L. E., Tanyi, J., Hagemann, A. R., Motz, G. T., Svoronos, N., Montone, K., Mantia-Smaldone, G. M., Smith, L., Nisenbaum, H. L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1185 · Cited by 218
“Treg cells have been associated with poor outcome in ovarian cancer (25) and experimentally depleting them has shown to be critical for tumor suppression (26).”
BackgroundSelf-citationNanoparticle‐based photothermal and photodynamic immunotherapy for tumor treatment
Hou, X., Tao, Y., Pang, Y., Li, X., Jiang, G., & Liu, Y. (2018) · International Journal of Cancer · doi:10.1002/ijc.31717 · Cited by 221
“Increasing the oxygen concentration in tumor tissues can reduce the immune system inhibition and enhance the T cell-mediated antitumor effect.(109,110) Although appearing to be more immunostimulatory than PTT, PDT alone exhibits highly limited stimulation and activation effects to both innate and adaptive immunity and…”
BackgroundHow to Improve the Survival of Transplanted Mesenchymal Stem Cell in Ischemic Heart?
Li, L., Chen, X., Wang, W. E., & Zeng, C. (2016) · Stem Cells International · doi:10.1155/2016/9682757 · Cited by 220
“…status in acute stage is another important factor causing the low retention of transplanted MSCs. Previous studies have shown that CD4 + CD25 hi FoxP3 + T regulatory (Treg) cells have a potential to suppress inflammation, thus providing a favorable environment for MSC engraftment [53, 111].”
Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma
Ma, Q., Long, W., Xing, C., Chu, J., Luo, M., Wang, H. Y., Liu, Q., & Wang, R.-F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02924 · Cited by 219
“Further, Treg recruitment is secondary to the release of these chemoattractants, implying that although Tregs may be necessary for tumor development, they are not contributing the initial establishment of the tumor (92, 93).”
BackgroundMetabolic control of the Treg/Th17 axis
Barbi, J., Pardoll, D., & Pan, F. (2013) · Immunological Reviews · doi:10.1111/imr.12029 · Cited by 217
“However, the revelation that hypoxic tumor masses readily recruit Foxp3-expressing Tregs (45, 46) that are likely induced elsewhere (47) offers a highly plausible alternative scenario in which HIF-1 may be degrading Foxp3 within the tumor along side a replenished Foxp3+ population thanks to newly infiltrating Tregs.”
BackgroundRegulatory T cells: a potential target in cancer immunotherapy
Shitara, K., & Nishikawa, H. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13625 · Cited by 214
Lactate dehydrogenase: a marker of diminished antitumor immunity
Van Wilpe, S., Koornstra, R., Den Brok, M., De Groot, J. W., Blank, C., De Vries, J., Gerritsen, W., & Mehra, N. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1731942 · Cited by 208
Molecular pathways: hypoxia response in immune cells fighting or promoting cancer
Palazón, A., Aragonés, J., Morales-Kastresana, A., de Landázuri, M. O., & Melero, I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1591 · Cited by 214
Becht, E., Giraldo, N. A., Germain, C., de Reyniès, A., Laurent-Puig, P., Zucman-Rossi, J., Dieu-Nosjean, M.-C., Sautès-Fridman, C., & Fridman, W. H. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2015.12.002 · Cited by 213
Chen, Y., Huang, Y., Reiberger, T., Duyverman, A. M., Huang, P., Samuel, R., Hiddingh, L., Roberge, S., Koppel, C., Lauwers, G. Y., et al. (2014) · Hepatology · doi:10.1002/hep.26790 · Cited by 211
“Increased SDF-1a expression can also lead to accumulation of tumor-promoting (proangiogenic and immune-suppressive) inflammatory cells.(18,25,48,49) We previously demonstrated that CXCR4 is critical for myeloid cell infiltration in tumors and can compensate for VEGFR1 inhibition in bone-marrow–derived cells by inhibit…”
Control of Regulatory T Cell Migration, Function, and Homeostasis
Campbell, D. J. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500801 · Cited by 208
“Similarly, inhibiting CCR10-mediated recruitment of Tregs to tumors could be used to augment antitumor immunity (89).”
BackgroundTargeting the tumour vasculature: from vessel destruction to promotion
Guelfi, S., Hodivala-Dilke, K., & Bergers, G. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00736-0 · Cited by 183
“…as angiopoietin-1 receptor) + monocytes, myeloid-derived suppressor cells (MDSCs), neutrophils and regulatory T (T reg ) cells that contribute to immune tolerance and re-neovascularization in tumours partly via the secretion of cocktails of pro-angiogenic and immunosuppressive factors 224–226 .”
Combinations of Bevacizumab With Cancer Immunotherapy
Chen, D. S., & Hurwitz, H. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000327 · Cited by 207
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Daniel, S. K., Sullivan, K. M., Labadie, K. P., & Pillarisetty, V. G. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0226-9 · Cited by 207
Role of TGFβ in regulation of the tumor microenvironment and drug delivery (Review)
PAPAGEORGIS, P., & STYLIANOPOULOS, T. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2816 · Cited by 206
Nanoscale CaH2 materials for synergistic hydrogen-immune cancer therapy
Gong, F., Xu, J., Liu, B., Yang, N., Cheng, L., Huang, P., Wang, C., Chen, Q., Ni, C., & Liu, Z. (2022) · Chem · doi:10.1016/j.chempr.2021.11.020 · Cited by 203
An, C., Shi, Y., Li, P., Hu, X., Gan, Y., Stetler, R. A., Leak, R. K., Gao, Y., Sun, B.-L., Zheng, P., et al. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.12.002 · Cited by 202
Chauhan, V. P., Chen, I. X., Tong, R., Ng, M. R., Martin, J. D., Naxerova, K., Wu, M. W., Huang, P., Boucher, Y., Kohane, D. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819889116 · Cited by 206
“Tumor TGF-β and hypoxia signaling can promote immunosuppression by increasing regulatory T lymphocyte function (15) and by driving exclusion of T lymphocytes from tumors (49, 50).”
BackgroundAbou Khouzam, R., Brodaczewska, K., Filipiak, A., Zeinelabdin, N. A., Buart, S., Szczylik, C., Kieda, C., & Chouaib, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613114 · Cited by 198
“Facciabene reported that tumor hypoxia also attracts Treg cells inside the tumor bed by impacting the cytokine profile (72).”
BackgroundThe tumor microenvironment’s role in the response to immune checkpoint blockade
Aliazis, K., Christofides, A., Shah, R., Yeo, Y. Y., Jiang, S., Charest, A., & Boussiotis, V. A. (2025) · Nature Cancer · doi:10.1038/s43018-025-00986-3 · Cited by 178
“…adhesion molecules, such as the common lymphatic endothelial and vascular endothelial receptor 1 (CLEVER-1), to selectively promote transmigration of T reg cells 110 while repressing transmigration of T eff cells, DCs, natural killer cells and neutrophils, thereby promoting tumor tolerance 111 .”
Mechanisms of Hypoxia-Mediated Immune Escape in Cancer
Barsoum, I. B., Koti, M., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2598 · Cited by 201
Hypoxia-inducible factors: a central link between inflammation and cancer
Triner, D., & Shah, Y. M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84430 · Cited by 199
“This effect was regulated by hypoxia-induced excretion of the chemokine CCL28, which was dependent upon HIF-1α and to a lesser extent HIF-2α (62).”
BackgroundWu, Y., Kyle-Cezar, F., Woolf, R. T., Naceur-Lombardelli, C., Owen, J., Biswas, D., Lorenc, A., Vantourout, P., Gazinska, P., Grigoriadis, A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax9364 · Cited by 199
Suppression, subversion and escape: the role of regulatory T cells in cancer progression
Oleinika, K., Nibbs, R. J., Graham, G. J., & Fraser, A. R. (2012) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2012.04657.x · Cited by 198
Interfering with Tumor Hypoxia for Radiotherapy Optimization
Telarovic, I., Wenger, R. H., & Pruschy, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02000-x · Cited by 185
The integrative roles of chemokines at the maternal–fetal interface in early pregnancy
Du, M.-R., Wang, S.-C., & Li, D.-J. (2014) · Cellular & Molecular Immunology · doi:10.1038/cmi.2014.68 · Cited by 196
Li, Y., Patel, S. P., Roszik, J., & Qin, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01591 · Cited by 195
“Tumor cells under hypoxia can also produce high levels of C-C motif chemokine ligand 28, which is an important chemokine to selectively attract CXCR10-positive Tregs in tumors resulting in antigen tolerance and angiogenesis (34).”
BackgroundRegulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment
Scott, E. N., Gocher, A. M., Workman, C. J., & Vignali, D. A. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.702726 · Cited by 190
“VEGF-A Frontiers in Immunology | www.frontiersin.org 5 produced by intratumoral CCR10+ Tregs in a CCL28-expressing murine ovarian tumor model, increased angiogenesis and tumor growth (30).”
BackgroundInfluentialPanagi, M., Voutouri, C., Mpekris, F., Papageorgis, P., Martin, M. R., Martin, J. D., Demetriou, P., Pierides, C., Polydorou, C., Stylianou, A., et al. (2020) · Theranostics · doi:10.7150/thno.36936 · Cited by 191
“and hypoxia hinder nanoparticle delivery but also help cancer cells evade the immune system and increase their invasive and metastatic potential [11-13].”
BackgroundBarriers to Radiation-Induced In Situ Tumor Vaccination
Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Pilones, K. A., García-Martínez, E., Rudqvist, N.-P., Formenti, S. C., & Demaria, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00229 · Cited by 194
“have demonstrated that hypoxic tumors promote the recruitment of Tregs via CCL28, which, in turn, dampen effector T cell function and promote angiogenesis (53).”
BackgroundTumor-Infiltrating Immune Cells Promoting Tumor Invasion and Metastasis: Existing Theories
Man, Y.-G., Stojadinovic, A., Mason, J., Avital, I., Bilchik, A., Bruecher, B., Protic, M., Nissan, A., Izadjoo, M., Zhang, X., et al. (2013) · Journal of Cancer · doi:10.7150/jca.5482 · Cited by 192
“The authors of this hypothesis believe that the recruitment of regulatory T cells to the tumors are mediated primarily through the CCL28-CCR10 interaction [99].”
BackgroundMethodHypoxia and Hypoxia Signaling in Tissue Repair and Fibrosis
(2012) · International Review of Cell and Molecular Biology · doi:10.1016/b978-0-12-394307-1.00003-5 · Cited by 190
Lei, H., Schmidt-Bleek, K., Dienelt, A., Reinke, P., & Volk, H.-D. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00184 · Cited by 186
Testa, U., Petrucci, E., Pasquini, L., Castelli, G., & Pelosi, E. (2018) · Medicines · doi:10.3390/medicines5010016 · Cited by 188
Liu, L., He, H., Luo, Z., Zhou, H., Liang, R., Pan, H., Ma, Y., & Cai, L. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201910176 · Cited by 186
Verginadis, I. I., Avgousti, H., Monslow, J., Skoufos, G., Chinga, F., Kim, K., Leli, N. M., Karagounis, I. V., Bell, B. I., Velalopoulou, A., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00918-8 · Cited by 181
Hendry, S. A., Farnsworth, R. H., Solomon, B., Achen, M. G., Stacker, S. A., & Fox, S. B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00621 · Cited by 188
“Hypoxic stress increases secretion of CCL28 and CXCL12 by tumor cells, thereby attracting regulatory T cells (142, 143).”
BackgroundChemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy
Bule, P., Aguiar, S. I., Aires-Da-Silva, F., & Dias, J. N. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189804 · Cited by 185
“In addition to CCR4, Treg cells can express other chemokine receptors capable of mediating their infiltration into the TME, such as CCR5 or CCR10, whose ligand CCL28 is found in hypoxic regions of the TME [32].”
BackgroundModulating Treg stability to improve cancer immunotherapy
Kang, J. H., & Zappasodi, R. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2023.07.015 · Cited by 182
Yan, Y., Sun, D., Hu, J., Chen, Y., Sun, L., Yu, H., Xiong, Y., Huang, Z., Xia, H., Zhu, X., et al. (2025) · Nature Genetics · doi:10.1038/s41588-024-01998-y · Cited by 170
Self-citationPalazón, A., Martínez-Forero, I., Teijeira, A., Morales-Kastresana, A., Alfaro, C., Sanmamed, M. F., Perez-Gracia, J. L., Peñuelas, I., Hervás-Stubbs, S., Rouzaut, A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0314 · Cited by 187
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Kandalaft, L. E., Dangaj Laniti, D., & Coukos, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00503-z · Cited by 180
Self-citationKucharzewska, P., & Belting, M. (2013) · Journal of Extracellular Vesicles · doi:10.3402/jev.v2i0.20304 · Cited by 186
“Accumulating data suggest a link between stress conditions of the tumour milieu and immunological tolerance of tumours (94).”
Nagl, L., Horvath, L., Pircher, A., & Wolf, D. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00766 · Cited by 180
“For example, hypoxia induces the up-regulation of HIF1α, the increased expression of CXCL12/CXCR4 and subsequent recruitment of TAM, MDSC, and Treg (Ebos and Kerbel, 2011) as well as it favors an M2-phenotype (Facciabene et al., 2011; Colegio et al., 2014) and reduces cytotoxic T cell activity (Calcinotto et al.”
BackgroundProfound Treg perturbations correlate with COVID-19 severity
Galván-Peña, S., Leon, J., Chowdhary, K., Michelson, D. A., Vijaykumar, B., Yang, L., Magnuson, A. M., Chen, F., Manickas-Hill, Z., Piechocka-Trocha, A., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111315118 · Cited by 185
“Hypoxia was one such factor, as it is a hallmark of tumors and an important factor in severe COVID-19 (28), and can promote Treg suppressive function (29).”
Nanoparticle‐Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor Efficacy
Zhen, W., Weichselbaum, R. R., & Lin, W. (2023) · Advanced Materials · doi:10.1002/adma.202206370 · Cited by 177
Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape
Chouaib, S., Messai, Y., Couve, S., Escudier, B., Hasmim, M., & Noman, M. Z. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00021 · Cited by 180
Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
Hompland, T., Fjeldbo, C. S., & Lyng, H. (2021) · Cancers · doi:10.3390/cancers13030499 · Cited by 179
Nanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178
Wu, V., Yeerna, H., Nohata, N., Chiou, J., Harismendy, O., Raimondi, F., Inoue, A., Russell, R. B., Tamayo, P., & Gutkind, J. S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.005601 · Cited by 179
Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential
Wang, L., Liang, Y., Zhao, C., Ma, P., Zeng, S., Ju, D., Zhao, M., Yu, M., & Shi, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02326-4 · Cited by 210
Self-citationHuang, D., Sun, L., Huang, L., & Chen, Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020124 · Cited by 176
“Thus far, 28 proangiogenic factors/genes have been found to mediate tumor angiogenesis [76,77], including the fibroblast growth factor (FGF), hypoxiainducible factor (HIF), platelet-derived growth factor-B (PDGF-B), tumor necrosis factor-α (TNF-α), chemokines, integrins, and transforming growth factor-β (TGF-β), as we…”
BackgroundEffects of tumor metabolic microenvironment on regulatory T cells
Wang, Y.-A., Li, X.-L., Mo, Y.-Z., Fan, C.-M., Tang, L., Xiong, F., Guo, C., Xiang, B., Zhou, M., Ma, J., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0913-y · Cited by 176
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 170
“It has been shown that multiple immune cells could be influenced by VEGF, including DCs, T cells, Tregs, and MDSCs.490 Both in animal models and humans, the inhibition of VEGF could increase the number of tumor-infiltrating lymphocytes.491,492 VEGF is also important for the expansion of the immunosuppressive MDSCs via…”
BackgroundReengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity
Martin, J. D., Fukumura, D., Duda, D. G., Boucher, Y., & Jain, R. K. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027094 · Cited by 175
“2013), and inflammation (Facciabene et al. 2011)—all contributing to tumor progression and treatment resistance (Jain 2014; Whatcott et al.”
BackgroundInterferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation
Stewart, C. A., Metheny, H., Iida, N., Smith, L., Hanson, M., Steinhagen, F., Leighty, R. M., Roers, A., Karp, C. L., Müller, W., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65180 · Cited by 173
“87, 88) were overexpressed in tumors from Ifnar1 −/− and Stat1 −/− mice (Figure 8).”
Metadata
- Authors
- Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., & Coukos, G.
- Affiliations
- University of Pennsylvania (US)
- University of British Columbia (CA)
- Corresponding author
- Coukos, George
- ORCID
- Venue
- Nature
- Published
- 2011-07
- Volume
- 475
- Issue
- 7355
- Pages
- 226-230
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142644858
- Cited by
- 1,376
- References
- 38
- Citations by year
- 2026: 54 · 2025: 90 · 2024: 112 · 2023: 113 · 2022: 151 · 2021: 152 · 2020: 119 · 2019: 105 · 2018: 77 · 2017: 85 · 2016: 74 · 2015: 55 · 2014: 55 · 2013: 69 · 2012: 50
- FWCI
- 26.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA116779, P01 CA 83638)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- tumor hypoxia, regulatory T cells, CCL28, chemokine recruitment, tumor angiogenesis, VEGF-A, tumor immune evasion, tumor growth, chemokines
- MeSH terms
- Animals, Female, Humans, Immune Tolerance, Mice, Inbred C57BL, Neovascularization, Pathologic, Ovarian Neoplasms, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Culture Media, Conditioned, Disease Progression, Chemokines, CC, Vascular Endothelial Growth Factor A, Cell Line, Tumor, T-Lymphocytes, Regulatory, Mice, Receptors, CCR10
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.